Why the study?
Hyperkalaemia carries significant burden, particularly in chronic disease states, and safe, well-tolerated therapies for long-term management were previously lacking.
The novel potassium binders patiromer and sodium zirconium cyclosilicate offer safe and effective long-term management of hyperkalaemia, potentially enabling the optimization of life-saving RAAS inhibitor therapy in patients with heart failure and resistant hypertension.
Novel binders expand long-term hyperkalaemia options in CV patients; leaves open confirmatory outcome trials.
Hyperkalaemia causes significant burden, and even mild hyperkalaemia has been independently associated with increased morbidity and mortality. Patients with chronic disease states, such as heart failure, hypertension, chronic kidney disease and diabetes mellitus, are increasingly susceptible to the development of hyperkalaemia. Options for management of hyperkalaemia had mainly been limited to short-term, temporizing methods with focus on rapid achievement of normokalaemia. Until recently, there was a lack of safe, efficacious and well-tolerated therapies for long-term management. Two novel potassium binders, patiromer and sodium zirconium cyclosilicate, have recently been approved by the US Food and Drug Administration for the management of hyperkalaemia. This review discusses these potassium binders with focus largely on the clinical implications of these agents in patients with chronic cardiovascular conditions.
No takes yet. Share an insight, caveat, or question.
Vijayakumar et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: